#1 Clinical Trials Search in Europe

Petosemtamab

Petosemtamab is an innovative drug currently being studied in clinical trials for the treatment of head and neck squamous cell carcinoma (HNSCC). These trials aim to evaluate the effectiveness and safety of Petosemtamab, either alone or in combination with other drugs, in patients with recurrent or metastatic HNSCC. The ongoing research focuses on comparing Petosemtamab to existing treatments and assessing its potential as a new option for patients who have not responded to previous therapies.

Table of Contents

What is Petosemtamab?

Petosemtamab, also known as MCLA-158, is a new drug being studied for the treatment of head and neck squamous cell carcinoma (HNSCC)[1][2]. This type of cancer affects the cells that line the mouth, throat, and other areas of the head and neck. Petosemtamab is a type of medication called a monoclonal antibody, which is a laboratory-made protein designed to target specific cells in the body.

What Condition Does Petosemtamab Target?

Petosemtamab is being developed specifically for patients with head and neck squamous cell carcinoma (HNSCC)[1][2]. This type of cancer can occur in various parts of the head and neck, including the mouth, throat, voice box, and sinuses. The drug is being studied for use in patients with:

  • Recurrent HNSCC (cancer that has come back after initial treatment)
  • Metastatic HNSCC (cancer that has spread to other parts of the body)

How Does Petosemtamab Work?

While the exact mechanism of action is not fully described in the provided information, as a monoclonal antibody, petosemtamab is designed to target specific proteins or cells in the body[1][2]. In the case of HNSCC, it likely targets proteins that are overexpressed or mutated in cancer cells, helping to slow down or stop the growth of these cells.

Current Clinical Trials

Petosemtamab is currently being studied in two major Phase 3 clinical trials:

  1. First-line Treatment Trial: This study is comparing petosemtamab plus pembrolizumab (another immunotherapy drug) to pembrolizumab alone in patients with recurrent or metastatic HNSCC who have not received previous systemic therapy for their advanced disease[1].
  2. Second- and Third-line Treatment Trial: This trial is comparing petosemtamab to the investigator’s choice of standard treatments (such as cetuximab, methotrexate, or docetaxel) in patients who have already received treatment with platinum-containing therapy and anti-PD-1 therapy (a type of immunotherapy)[2].
These trials aim to determine how effective and safe petosemtamab is compared to current standard treatments.

Potential Benefits of Petosemtamab

The clinical trials are designed to measure several potential benefits of petosemtamab, including[1][2]:

  • Objective Response Rate (ORR): This measures how many patients see their tumors shrink or disappear after treatment.
  • Overall Survival (OS): This looks at how long patients live after starting the treatment.
  • Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse.
  • Duration of Response (DOR): For patients whose tumors do shrink or disappear, this measures how long that improvement lasts.
The researchers hope that petosemtamab will show improvements in these areas compared to current treatments.

Possible Side Effects

As with all medications, petosemtamab may cause side effects. The clinical trials are carefully monitoring for any adverse events (side effects) that patients may experience[1][2]. These may include:

  • Treatment-Emergent Adverse Events (TEAEs): Any new medical problems that develop during the treatment.
  • Serious TEAEs: Side effects that are severe or life-threatening.
  • Side effects that may require stopping the treatment or changing the dose.
The full range of potential side effects is not yet known, as the drug is still in the testing phase. Patients in the trials will be closely monitored for any unexpected reactions.

Future Prospects

If the ongoing clinical trials show positive results, petosemtamab could become an important new treatment option for patients with head and neck cancer[1][2]. It may offer hope to patients who have not responded well to current treatments or whose cancer has returned after initial therapy. However, it’s important to remember that the drug is still in the testing phase, and more research is needed to fully understand its effectiveness and safety profile.

Aspect Details
Drug Name Petosemtamab (MCLA-158)
Target Condition Head and Neck Squamous Cell Carcinoma (HNSCC)
Trial Phases Phase 3
Trial Types Randomized, Open-label
Comparisons 1. Petosemtamab + Pembrolizumab vs. Pembrolizumab alone
2. Petosemtamab vs. Investigator’s Choice (Cetuximab, Methotrexate, or Docetaxel)
Primary Outcomes Objective Response Rate (ORR), Overall Survival (OS)
Secondary Outcomes Progression-Free Survival (PFS), Duration of Response (DOR), Safety and Tolerability
Patient Population Recurrent or Metastatic HNSCC patients, including those who have progressed on previous therapies
Trial Duration Up to approximately 2-3 years

FAQ

  • What is Petosemtamab? Petosemtamab, also known as MCLA-158, is a new drug being tested in clinical trials for the treatment of head and neck squamous cell carcinoma (HNSCC). It is being studied both as a standalone treatment and in combination with other drugs.
  • What type of cancer is being targeted in these clinical trials? The clinical trials are focusing on head and neck squamous cell carcinoma (HNSCC), specifically in patients with recurrent or metastatic disease.
  • How is Petosemtamab being compared to other treatments? In one trial, Petosemtamab is being combined with Pembrolizumab and compared to Pembrolizumab alone. In another trial, Petosemtamab is being compared to the investigator's choice of treatment, which could include drugs like Cetuximab, Methotrexate, or Docetaxel.
  • What are the main outcomes being measured in these trials? The main outcomes being measured include Objective Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), and Duration of Response (DOR). The trials are also assessing the safety and tolerability of Petosemtamab.
  • How long do these clinical trials last? The trials are designed to last up to approximately 2-3 years, with some outcomes being measured for up to 3 years and safety assessments continuing for up to 30 days after the last dose of the study drug.

Ongoing Clinical Trials on Petosemtamab

  • A study to evaluate the safety and effectiveness of petosemtamab and pembrolizumab in adults with non-small cell lung cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Italy The Netherlands Poland Spain

  • Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Greece Hungary +6

  • Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Croatia Czechia France Germany +8

  • Study of petosemtamab alone or with drug combination for patients with advanced colorectal cancer and other solid tumors

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium France Italy The Netherlands Spain

Glossary

  • Head and Neck Squamous Cell Carcinoma (HNSCC): A type of cancer that begins in the squamous cells that line the moist surfaces inside the head and neck, such as the mouth, nose, and throat.
  • Petosemtamab: An investigational drug, also known as MCLA-158, being studied for the treatment of head and neck squamous cell carcinoma.
  • Pembrolizumab: A humanized antibody used in cancer immunotherapy, particularly for treating various types of cancer including HNSCC.
  • Recurrent or Metastatic: Recurrent means the cancer has come back after treatment. Metastatic refers to cancer that has spread from its original site to other parts of the body.
  • PD-L1+: Refers to cancers that express the PD-L1 protein, which can help cancer cells evade the immune system.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Duration of Response (DOR): The length of time that a tumor continues to respond to treatment without growing or spreading.
  • RECIST v1.1: Response Evaluation Criteria in Solid Tumors version 1.1, a standard way to measure how well a cancer patient responds to treatment.
  • Blinded Independent Central Review (BICR): A method where treatment responses are assessed by independent experts who do not know which treatment each patient received.
  • Adverse Events (AEs) and Serious Adverse Events (SAEs): Undesired harmful effects resulting from a medication or treatment. Serious adverse events are those that may lead to death, hospitalization, or significant disability.

References

  1. https://clinicaltrials.gov/study/NCT06525220
  2. https://clinicaltrials.gov/study/NCT06496178